Offering Details - uniQure announced the pricing of its underwritten public offering of 4,411,764 ordinary shares at $17.00 per share, with expected gross proceeds of approximately $75 million before deductions [1] - The company granted underwriters a 30-day option to purchase up to 661,764 additional ordinary shares at the public offering price, less underwriting discounts and commissions [1] - The offering is expected to close on or about January 10, 2025, subject to customary closing conditions [1] Underwriters and Prospectus - Leerink Partners, Stifel, and Guggenheim Securities are acting as the bookrunning managers, while Chardan and H.C. Wainwright & Co. are the lead managers for the offering [2] - The securities are offered pursuant to uniQure's automatically effective shelf registration statement filed with the SEC on January 7, 2025 [3] - A preliminary prospectus supplement and accompanying prospectus were filed with the SEC, and the final versions will be filed and made available through the underwriters [3] Company Overview - uniQure is a leading gene therapy company focused on developing transformative therapies for severe medical needs [5] - The company has achieved a historic milestone with the approval of its gene therapy for hemophilia B, representing a major advancement in genomic medicine [5] - uniQure is advancing a pipeline of proprietary gene therapies for Huntington's disease, refractory temporal lobe epilepsy, ALS, Fabry disease, and other severe diseases [5]

LEXINGTON, Mass. and AMSTERDAM, Jan. 07, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it has commenced an underwritten public offering of its ordinary shares and pre-funded warrants to purchase its ordinary shares. All securities to be sold in the offering will be offered by uniQure. In addition, uniQure intends to grant the underwriters a 30-day option to purchase up to 15% ...

Shares of the international gene therapy developer uniQure (QURE 2.26%) have been soaring. Investors are responding to positive news regarding the Food and Drug Administration (FDA) and the company's Huntington's disease candidate.During the first 12 days of December, shares of uniQure rocketed 152% higher, and investors want to know if this stock has legs that can propel it further in 2025. Let's weigh the positive news that drove the stock through the roof against some challenges the drugmaker faces to se ...

uniQure N.V. (QURE) surged 109.7% after it announced reaching alignment with the FDA on key elements of an accelerated approval pathway for AMT-130, a one-time administered investigational gene therapy, which is being developed to treat Huntington’s disease.Huntington's disease is a genetic disorder that causes the progressive breakdown of nerve cells in the brain, which leads to a decline in cognitive and physical abilities, often resulting in movement, thinking and psychiatric problems. uniQure enjoys the ...

Shares of uniQure (QURE) have gained 5.2% over the past four weeks to close the last trading session at $6.02, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $19.75 indicates a potential upside of 228.1%.The average comprises 12 short-term price targets ranging from a low of $7 to a high of $28, with a standard deviation of $8.05. While the lowest estimate indicates an increase ...

uniQure (QURE) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.Since a changing ...

uniQure (QURE) closed the last trading session at $7.43, gaining 37.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $20 indicates a 169.2% upside potential.The average comprises 12 short-term price targets ranging from a low of $7 to a high of $28, with a standard deviation of $7.82. While the lowest estimate indicates a decline of 5.8% from the current price level, the most opt ...

UniQure (QURE) came out with a quarterly loss of $0.91 per share versus the Zacks Consensus Estimate of a loss of $1.12. This compares to loss of $1.88 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 18.75%. A quarter ago, it was expected that this human gene therapy company would post a loss of $1.24 per share when it actually produced a loss of $1.16, delivering a surprise of 6.45%.Over the last four quarters, the company ha ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission file number: 001-36294 uniQure N.V. (Exact name of Registrant as specified in its charter) The Netherlands ...

Exhibit 99.1 uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress ~ Type B meeting scheduled with the FDA in the fourth quarter of 2024 to initiate discussions regarding a potential expedited clinical development pathway for AMT-130 in Huntington's disease ~ ~ Presented positive interim data from Phase I/II trial of AMT-130 demonstrating slowing of Huntington's disease progression and reductions in key biomarker of neurodegeneration ~ ~ Initiated patient dosing in ne ...